Immune Checkpoint Inhibitor‐Related Myocarditis: A Single Center Observational Registry
Clinical Cardiology · 2025
DOI: 10.1002/clc.70154 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Grace Alexander und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors, Registries, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Introduction
Immune checkpoint inhibitors (ICIs) are associated with myocarditis, which is rare but has a high mortality. This study aimed to describe cases of ICI‐related myocarditis at the University of Iowa Hospitals & Clinics and, in doing so, provide valuable insights into patient characteristics, treatment, and outcomes.
Methods
This single‐center observational registry included cases of ICI‐related myocarditis identified from 2009 to 2024. Data were collected retrospectively from electronic medical records and included demographics, cardiovascular risk factors, medications, and cancer characteristics. Between‐group comparisons for continuous data were conducted using unpaired Student's t ‐tests or the Wilcoxon rank‐sum test. Categorical data were analyzed with Fisher's exact test.
Results
Eighteen patients were included. The mean age was 74 ± 9.4 years with 61% being male. Compared to controls, patients with ICI‐related myocarditis had a significantly higher prevalence of coronary artery disease (36.8% vs. 7.5%, p = 0.01) and obstructive sleep apnea (33% vs. 10%, p = 0.03). They were less likely to have a normal sinus rhythm on baseline electrocardiogram (50% vs. 70%, p < 0.01) and more likely to suffer from a major adverse cardiac event (MACE) (38.9% vs. 2.5%, p < 0.01). Twelve (66.7%) of patients with ICI‐related myocarditis also had myasthenia gravis‐like overlap syndrome and 9 (50%) had myositis/rhabdomyolysis.
Conclusions
ICI‐related myocarditis at a tertiary care center is rare with a calculated incidence of 0.48%. Despite this, the disease has a high incidence of MACE. Patients with pre‐existing cardiovascular disease are at higher risk of developing ICI‐related myocarditis. Careful cardiovascular monitoring in patients undergoing ICI therapy is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
- Department of Medicine, Division of Cardiology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
- Department of Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
ORCID-Profile: Grace Alexander
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Alexander, G., Mortada, I., Mhanna, M., Byer, S., Grewal, U. S., & Mansour, S. (2025). Immune Checkpoint Inhibitor‐Related Myocarditis: A Single Center Observational Registry. Clinical Cardiology. https://doi.org/10.1002/clc.70154
Vancouver
Alexander G, Mortada I, Mhanna M, Byer S, Grewal US, Mansour S. Immune Checkpoint Inhibitor‐Related Myocarditis: A Single Center Observational Registry. Clinical Cardiology. 2025. doi:10.1002/clc.70154
BibTeX
@article{Alexander2025,
author = {Alexander, Grace and Mortada, Ibrahim and Mhanna, Mohammed and Byer, Stefano and Grewal, Udhayvir Singh and Mansour, Shareef},
title = {Immune Checkpoint Inhibitor‐Related Myocarditis: A Single Center Observational Registry},
journal = {Clinical Cardiology},
year = {2025},
doi = {10.1002/clc.70154}
}
EUVIMED